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Abstract The interactions among associating (macro)mol-
ecules are dynamic, which adds to the complexity of
molecular recognition. While ligand flexibility is well
accounted for in computational drug design, the effective
inclusion of receptor flexibility remains an important
challenge. The relaxed complex scheme (RCS) is a
promising computational methodology that combines the
advantages of docking algorithms with dynamic structural
information provided by molecular dynamics (MD) simu-
lations, therefore explicitly accounting for the flexibility
of both the receptor and the docked ligands. Here, we
briefly review the RCS and discuss new extensions and
improvements of this methodology in the context of ligand
binding to two example targets: kinetoplastid RNA editing
ligase 1 and the W191G cavity mutant of cytochrome
c peroxidase. The RCS improvements include its extension
to virtual screening, more rigorous characterization of local
and global binding effects, and methods to improve its
computational efficiency by reducing the receptor ensem-
ble to a representative set of configurations. The choice of
receptor ensemble, its influence on the predictive power of
RCS, and the current limitations for an accurate treatment
of the solvent contributions are also briefly discussed.
Finally, we outline potential methodological improvements
that we anticipate will assist future development.
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Abbreviations
GA Genetic algorithm
KREL1 Kinetoplastid RNA editing ligase 1
MD Molecular dynamics
RCS Relaxed complex scheme
RMSD Root-mean-square deviation
W191G W191G cavity mutant of cytochrome
c peroxidase
Introduction
A full understanding of molecular recognition presents a
problem of intense interest to the field of computer-aided
drug design and molecular sciences in general. The inter-
actions between ligand molecules and their corresponding
receptors are dynamic and complex. Techniques that best
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address these issues must account for the conformational
flexibility of both the ligand and the receptor and do so in
an accurate and efficient manner. While the ability to
explore ligand flexibility is well established, computer-
aided drug design methodologies have only recently begun
to take receptor flexibility into account when searching for
and optimizing functional inhibitors. Since it is widely
accepted that ligands may bind to receptor conformations
that occur infrequently in the receptor’s dynamics, and that
the local motions of active site residues can drastically alter
the binding and specificity of ligands to their target, the
ability to efficiently sample these rare dynamics and fur-
thermore, to incorporate the resulting conformations into
the drug design protocol, remains an important challenge
(reviewed in references [1–5]).
A closely related challenge is the development of effec-
tive methods to predict the binding propensity for series
of compounds or flexible peptides to a given receptor [6–11].
Approaches based on scoring functions or compound
libraries require large amounts of data to be available a
priori. These methods include computational virtual
screening [12–18], docking [18–23], and similarity search-
ing [24, 25]. More advanced treatments of receptor–ligand
binding can be achieved using molecular dynamics (MD)
simulations. Free energy changes can then be estimated
based on coupling-parameter approaches, such as thermo-
dynamic integration (TI) and free energy perturbation (FEP)
[11, 26–36], which describe a higher physical complexity of
the binding process and include an extensive sampling of
receptor, ligand, and solvent phase spaces. Importantly, the
latter methods provide not only binding free energy esti-
mates, but also a reliable measure of their accuracy. Yet,
they are typically too computationally expensive to be
applied to extensive sets (*105) of compounds, which is the
usual scenario for newly discovered biological targets.
Hybrid methods, which are faster but more approximate,
have been developed with the aim of reducing a large
initial set of potential binders (*103 or more), to a reduced
set of promising molecules (*101), for which the binding
properties can then be investigated in a second phase that
uses more rigorous methods to predict binding free ener-
gies (Fig. 1). Examples of these hybrid methods are linear
interaction energy (LIE) [37–39], single-step perturbation
[40–45], docking to MD structures [44, 46], docking to
relevant normal modes structures [47–49], induced-fit
docking (IFD) [50], the dynamic pharmacophore model
[51, 52] and the relaxed complex scheme (RCS) [53–55].
Alternatively, the receptor ensemble can be gathered from
a collection of independent X-ray or NMR experimentally
derived structures [56, 57]. These hybrid approaches
encompass different levels of accuracy, predictive power,
and level of a priori knowledge required. For example, LIE
and single-step perturbation can be considered ‘‘non-
empirical’’ in that they are derived from free energy type
approaches and based on more complex physical models of
the binding process. Yet, in practice they need precise
information on the location of the binding site to be
available a priori. Conversely, docking-based techniques
are appealing for screening purposes because they do not
necessarily require any information on the location of the
binding site, and can therefore be employed to predict
binding site locations. In principle, these docking-based
approaches should also be more easily extendable to bio-
logically relevant systems with increasing size and
complexity, such as protein–nucleotide and protein–protein
association. However, they cannot supply accurate esti-
mates of free energy changes upon binding.
The RCS is a promising computational methodology
that combines the advantages of docking algorithms
with dynamic structural information provided by MD
Fig. 1 The problem: how to
distill a few good binders and
characterize their binding
propensity out of a vast database
of compounds
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simulations, explicitly accounting for the flexibility of
both the receptor and docked ligands. This procedure is
appealing as a large variety of conformational changes
may characterize ligand binding processes of biochemical
and medical interest and, more generally, molecular rec-
ognition. The RCS has been developed in combination
with various MD software packages and AutoDock for the
ligand docking. Although other docking programs can be
considered, all RCS applications to date have employed
AutoDock, a widely distributed and tested docking pro-
gram that has been shown to be successful in a variety of
docking studies [20–22]. The RCS was first applied to the
FKBP binding protein [53] and tested using improved re-
scoring functions based on MM-PBSA models [54].
Applications of the RCS identified a novel-binding trench
in HIV integrase [55]. In this work, we sketch the phi-
losophy underlying the RCS, describe new improvements,
and present recent applications to exemplify the type of
problems that can be tackled with this computational
scheme.
Materials and methods
Relaxed complex scheme: short overview
In the typical RCS (Fig. 2), all-atom MD simulations are
carried out for the target biomolecule of interest, with a
substrate or inhibitor bound in the active site, starting from
the crystal structure with a bound ligand (i.e., the holo
complex). Typical simulation lengths range from 2 ns to
tens of ns, and snapshots of the biomolecule are extracted
at a predetermined time interval (e.g., every 10 ps). RCS
calculations based on explicit solvent MD simulations of
two different systems are presented in this work. First, the
kinetoplastid RNA editing ligase 1 (KREL1), which uses
the NAMD2.6 MD software [58] (freely available at http://
www.ks.uiuc.edu/Research/namd/) with the Charmm27 force
field [59]. Second, the W191G cavity mutant of cytochrome c
peroxidase (W191G), based on simulations performed with
the GROMOS05 software for biomolecular simulation [60]
(available at http://www.igc.ethz.ch/gromos/) using the 45A4
Fig. 2 An overview of the RCS. Improvements to the RCS are shown
in gray background and those specifically presented in this paper are
outlined in red. In the ‘‘Receptor Ensemble’’ box (top left), the
structures can be generated with classical MD, or a variety of simula-
tion techniques could be considered in order to enhance the sampling
of the receptor configurational space, including: Generalized-Born
MD (GB-MD), steered MD (SMD), high temperature MD (High T
MD), targeted MD (TMD), and accelerated MD (Accl. MD). In the
‘‘Ligand Ensemble’’ box (top right), commercially or publicly
available ligands can be found in the Zinc Is Not Commercial
(ZINC), National Cancer Institute (NCI), and Available Chemicals
Database (ACD), among others. AutoDock is then used to dock the
ligand database into the receptor ensemble. In the ‘‘Post-Processing’’
stage, the docked complexes can be rescored or reevaluated using
more rigorous protocols than the AutoDock version 4.0 scoring
function (AD4), including molecular-mechanics Poisson–Boltzmann
surface area (MM-PBSA), single step perturbation, LIE, and FEP or
TI techniques
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parameter set [61] of the GROMOS force field [62]. Details
of the MD for each system are described in References [63]
and [64], respectively. The resulting set of structures, gen-
erated with a physically based MD force field, represents the
receptor ensemble and can be conceptually thought of as a set
of structures defining approximately its thermodynamic
equilibrium state in solution. This receptor ensemble is sub-
sequently used in the docking experiments, in which a
reduced set of small molecules are docked into the active site
and the corresponding binding affinities are evaluated.
AutoDock is used to carry out the docking experiments
and full ligand flexibility is employed. One of the major
advantages of AutoDock is its use of a hybrid genetic algo-
rithm (GA) to perform an efficient and effective global
search for the ligand [65]. Genetic algorithms are optimi-
zation schemes that use the language of natural genetics and
evolution, and in the case of AutoDock, the optimization
problem is molecular docking between a ligand and a
receptor. Typically, the receptor is fixed and the translation,
orientation, and conformation of the ligand are explored.
Genetically derived terms such as the AutoDock ‘‘chromo-
some,’’ which describes the ligand state, define its
‘‘genotype’’ and the atomic coordinates of the ligand, which
describes its ‘‘phenotype,’’ undergo genetic events such as
‘‘selection, crossover, and mutation’’ during the optimiza-
tion procedure.
The AutoDock chromosome consists of a string of real-
valued genes containing three cartesian coordinates for
ligand translation, four variables defining a quaternion that
specifies the ligand orientation, and one real-value for each
ligand torsion [65]. The global search is carried out on the
genotype level and performed with the GA, which allows
selection, crossover, and mutation. The ligand-receptor
fitness is evaluated based on a semi-empirical scoring
function including an empirical estimate for the ligand
configurational entropy [66]. The global search is followed
by an adaptive-stepping local search that performs energy
minimizations on the atomic coordinates. Afterwards, the
optimized phenotype is fed back to the genotype, in
accordance with ‘‘Lamarckian’’ genetics, from which the
algorithm derives its name. Ultimately, solutions better
suited to specific interactions have a better score, therefore
reproduce and persist, whereas poorer suited ones die off.
The re-docking of the ligands across the ensemble of
receptor structures results in a range of predicted binding
affinities for each ligand, based on the AutoDock scoring
function. The resulting ‘‘binding spectrum’’ for each ligand
is then used to reorder the ligands and better predict rela-
tive affinity. Various post-processing options can be
considered beyond the initial affinity estimate provided by
AutoDock, including the application of MM-PBSA, single-
step perturbation, LIE, FEP, or TI (Fig. 2). Although more
rigorous free energy estimates increase the confidence in
the predicted binding energies, they can be prohibitively
computationally expensive.
Improved relaxed complex scheme
A first set of improvements involves the docking algorithm
itself as implemented in AutoDock version 4.0: (i) a more
complete thermodynamic cycle, where the unbound (gas
phase) ligand enthalpy is computed, (ii) an improved des-
olvation term that accounts for a larger number of atom
types than in the previous versions, and (iii) a charge model
that allows fast calculation of the charge distribution [67]
and compatibility of partial charges between the ligand and
the receptor structures [66]. The studies presented here
employed this new and improved version of AutoDock
(freely available at http://www.autodock.scripps.edu/).
A second set of improvements involves the RCS meth-
odology itself, as described in the following, based on
recent applications. The first extension to the RCS we
present here is the application of the method for virtual
screening, which involves an essential enzyme for the
protozoan parasite Trypanosoma brucei. The discovery of
several new inhibitors was the result of a streamlined RCS
method, providing a concrete example of its success when
trying to discover new inhibitors from a large database of
compounds [68]. The second methodological advancement
for RCS involves accounting for both local-induced and
global effects of ligand binding. This is shown with the
well-characterized binding of a set of heterocyclic cation
ligands to the W191G cavity mutant of cytochrome c
peroxidase [69]. The third improvement attempts to define
two general algorithms to reduce the number of MD tra-
jectory snapshots for the docking experiments, which
increases computational efficiency by orders of magnitude
without decreasing its accuracy. First, the KREL1 appli-
cation uses the QR factorization method available in the
MultiSeq plugin in VMD [70]. Second, the W191G cavity
mutant of cytochrome c peroxidase (W191G) uses an
atom-positional root-mean-square deviation (RMSD)
clustering algorithm [71] as implemented in the rmsdmat2
and cluster2 programs of the GROMOS++ analysis soft-
ware [60]. Last, we discuss the importance and the
difficulties of including explicit water molecules within the
binding sites in the RCS docking experiments.
New applications
RCS as a tool for enhanced virtual screening
Given a novel protein target, the goal of identifying a new
set of potential inhibitors with drug-like properties can be
achieved using virtual screening type approaches. Typically
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these large-scale virtual screens are carried out by evalu-
ating the predicted affinities of thousands of molecules
against a single static crystal structure [15, 72]. Here we
report on the success of porting the RCS into a virtual
screen type application in the search for inhibitors against
an essential kinetoplastid RNA editing ligase 1 (KREL1)
in T. brucei, the parasite responsible for the devastating
tropical disease African sleeping sickness [68]. KREL1 is
required for survival of both the insect and bloodstream
forms of the parasite [73], and it is a particularly attractive
drug target as there are no known human homologues. The
high-resolution crystal structure [74] provides an excellent
platform for computer-aided drug design as well as for MD
simulations and the RCS application.
The KREL1 crystal structure revealed a deep active site
pocket with several water molecules coordinated to the
ATP substrate and the protein. Two 20 ns simulations in
explicit solvent were carried out with KREL1, both with
and without the bound ATP in order to generate the
receptor ensembles [63]. A screen of the crystal structure
against the NCI diversity set (containing 1,900 compounds)
using AutoDock version 4.0 was performed, and the top
twenty-five compounds that obeyed most of Lipinski’s
‘‘rules of 5’’ [75] were selected for application of the RCS
method. The top 25 ligands were then re-docked into the
full receptor ensemble as well as a reduced representative
set (discussed in further detail below) and these compounds
were then re-ranked based on their average binding energy
of the most populated cluster.
The results of the RCS virtual screen with KREL1 are
particularly promising. Several new inhibitors have been
identified with the RCS and an in vitro inhibition assay of
the first step in the binding reaction, the adenylation step,
was used to verify the computational predictions. These
experiments confirmed two of the eight tested compounds
found in the initial screen were inhibitory [68]. Impor-
tantly, the RCS method resulted in a reordering of the
twenty-five compounds that identified inhibitors that would
not have otherwise been tested, based on their rank from
the static crystal structure screen. Specifically, the best hit
as experimentally verified was initially ranked fifteenth,
and after RCS reordering became first. In the case of
limited resources and low-throughput experimental proce-
dures, where only a handful of the best compounds
identified in the screen could be experimentally tested, the
application of the RCS method provided a measurable and
important enrichment of the initial ranked set.
Accounting for induced fit and the global effects
of ligand binding
In nature, a great number of protein–ligand recognition
processes are only possible when accompanied by local
(i.e., the reorganization of residues upon induced-fit bind-
ing) or global (i.e., larger scale conformational changes
occurring also in remote structural elements of the receptor
upon binding) effects. Our current structural knowledge of
biomolecular association phenomena is predominantly
based on X-ray crystallography ensemble-averaged struc-
tures. Although these experiments provide critical binding
information, they typically capture only one state involved
in the binding process, which may be a dominant configu-
ration, but not necessarily exclusive. Dynamic information
at the atomistic level, as provided by MD simulations, is of
fundamental importance and may reveal binding modes and
relevant biophysical information otherwise inaccessible to
standard experimental techniques.
A relevant example of the importance of predicting
receptor-flexibility effects resulted from the application of
RCS to HIV integrase. MD simulations of the integrase
protein bound to a known inhibitor revealed a new cavity
adjacent to the active site [55]. RCS docking of ligands into
this newly discovered pocket indicated favorable binding
of ligands to this area. This new structural insight was
exploited in the development of raltegravir (MK-0518), the
first of a new class of antiretroviral agents active against
the enzyme integrase that has recently been approved by
the FDA [76].
As the binding propensity defining a given molecular
association reflects the relative stabilities of the possible
conformations of the receptor, effective drug-design pro-
tocols should be based on a distribution of receptor
conformations. In this respect, RCS has the advantage of
requiring the generation of only one MD ensemble per
receptor macro-state (e.g., the open or closed state of a loop
gating the binding pocket). This has recently been sys-
tematically investigated in the case of the W191G cavity
mutant of cytochrome c peroxidase by analyzing the
docking of small ligands into alternative ensembles of
receptor conformations [69].
The binding of heterocyclic cation ligands into the
W191G engineered cavity has been characterized experi-
mentally [77–81]. Mutation of this key tryptophan in the
active site creates a ligand-binding cavity and also appears
to increase local flexibility, which opens a loop-gated
pathway for ligands to reach the buried cavity. Recently,
MD simulations suggested the importance of induced-fit
effects in the W191G cavity for binding of 2-amino-5-
methylthiazole (2a5mt) [64]. X-ray crystallography
experiments have elucidated the structures of several
ligand-protein complexes, including those for which the
loop rearrangement is more pronounced and causes a shift
between the closed- and open-gate structural ensembles.
Benzimidazole (bzi) was suggested to produce a full
opening of the cavity [78]. MD simulations starting
from different initial configurations characterized the
J Comput Aided Mol Des (2008) 22:693–705 697
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conformational sampling and dominant configurations of
the closed and open alternate states (Fig. 3a).
RCS calculations were performed on different gating-
loop and binding states: the closed-gate apo, the closed-
gate holo (i.e., the complex with the best binder), and the
open-gate apo structure, allowing the investigation of the
correlation between each compound’s binding affinity and
the closed/open state of the gating loop (Fig. 3b) [69].
Additional in silico experiments evaluated the benefits of
using non-standard MD trajectories to enhance the con-
formational sampling (e.g., simulations at high temperature
using atom-positional restraining potentials) or simulate an
unphysical generalized-ligand interaction encompassing
the characteristics of all potential binders [69]. In the case
of 2a5mt, the optimal binding spectrum occurs when
docked into the receptor conformations from the holo
ensemble. Although both the holo and apo receptor
ensembles generate ligand-binding poses (i.e., the geome-
try of a docked ligand into the binding site) that are similar
to those determined experimentally, the 2a5mt binding
affinities are closer to the experimental results for the holo
ensemble (Fig. 3c). This illustrates that the holo ensemble
is the best choice to perform RCS calculations for the
2a5mt ligand, and suggests the same is likely the case for
other ligands with similar chemical and electrostatic
properties [69].
A different picture emerges when bzi binds to the same
cavity. In this case, the best agreement between RCS
affinities and the experimental free energies is found when
using the apo-open receptor ensemble. This agrees with the
experimental observation that bzi shifts the propensity of
the gating-loop configurations towards the open-gate state.
Fig. 3 (a) The W191G cavity mutant of cytochrome c peroxidase
and its two dominant configurations extracted using an RMSD
conformational clustering analysis for the gating-loop and MD
simulations of the separate states. The closed (blue) and open
(yellow) gate states are highlighted, together with Asp 235, the
residue determining the orientation of the binders in the cavity. The
heme cofactor is shown in red. (b) Binding propensities of the best
binder (2a5mt) and of the binder suggested to induce the full opening
of the gating loop (bzi) are shown [69]. For each of the two
conformational states of the gating loop the probability distributions
of the binding affinities from RCS calculations are shown as based on
the apo (black), holo (red), and apo open-gate (green) receptor
ensemble simulations. The dashed-vertical lines correspond to the
experimental free energies of binding. Docking poses for 2a5mt (c)
and bzi (d) are displayed from corresponding crystal structures
(yellow) and the RCS calculations based on MD simulations of the
apo (black), holo (red), and apo open-gate (green) receptors
698 J Comput Aided Mol Des (2008) 22:693–705
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Again, the ligand-binding poses (i.e., the relative orienta-
tion of the docked ligand into the W191G artificial cavity)
are very similar between the RCS method and the crys-
tallographic complexes (Fig. 3c). Although a false negative
is found when docking bzi to the ensemble of apo receptor
structures, bzi binds favorably and with a binding mode
similar to experiment when using the closed-gate holo
ensemble (Fig 3d). These promising results suggest that it
may be possible to capture different binding propensities
depending on both local and global receptor rearrange-
ments upon binding.
Effective reduction of the receptor ensemble
In the original RCS, the computational docking experi-
ments were carried out using snapshots extracted at equal
time intervals from the MD trajectories. As the simulations
are carried out for several nanoseconds, this typically sums
up to *104 to 105 receptor structures, many of which may
be conformationally redundant. Two recent studies have
investigated alternative methods to distill the structural
information to a reduced, yet meaningful set.
A novel method to distill the ensemble of structures to a
non-redundant set is the so-called ‘‘QR factorization’’
method. This technique was originally developed to
remove inherent bias in structure databases and distill, from
a vast quantity of redundant information, a minimal basis
set of protein structures that accurately spans the evolu-
tionary phase space of a particular protein [82]. It has also
been applied to an ensemble of NMR structures in order to
determine a small, representative subset of structures from
a larger experimental dataset [83] and to create non-
redundant sequence alignments [84]. This technique has
most recently been incorporated into the RCS, where a
multiple structural alignment of the receptor ensemble is
performed with STAMP [85]. This alignment algorithm
operates progressively: all possible pair-wise alignments
are computed, followed by a hierarchical clustering anal-
ysis based on a structural similarity measure to build the
multiple structural alignment. The measure of structural
similarity applied here is QH, which essentially measures
the distance between all pairs of Ca atoms among all
aligned structures. Although the development of QH was
motivated by the need to include gaps in order to build a
similarity measure for more distantly related proteins, in
the case of aligning the receptor ensemble, the gap term is
unnecessary as structures of the same protein are aligned.
The structural alignment is stored in a multidimensional
matrix of dimension maln 9 nreceptor structures 9 d, where d
encodes the rotated Ca atoms coordinates. In this matrix,
each receptor structure is represented in a column and
the rows represent the multiple alignment. Finally, a
multi-dimensional QR factorization algorithm is applied to
the encoded alignment of receptor structures, which results
in a reordering of the structures based on increasing linear
dependence. This reordering subsequently allows the
construction of non-redundant sets of structures at some
user-defined cutoff, representing a certain dynamical con-
figuration space.
The application of this method to the receptor ensemble
of RNA editing ligase 1 resulted in the initial set of 400
structures (extracted every 50 ps from a 20 ns simulation)
being reduced to 33, with essentially no loss of binding
spectrum information (Fig. 4a). When docking a large set
of ligands, as is required in a virtual-screen type applica-
tion, the reduction of receptor structures for the
computational dockings can make a significant difference
in computational cost. For example, for RNA editing
ligase, the number of dockings was reduced from 11,200 to
924, resulting in a 90% reduction of computational cost
[68].
An alternative method is clustering based on a matrix of
all pair-wise RMSD of the aligned structures in the
receptor ensemble. If the binding region of the receptor is
known a priori the clustering algorithm can focus on this
particular subset of residues that constitute the binding site.
The employed algorithm was originally developed to cap-
ture the dominant configurations of an ensemble of
structures for flexible peptides [71] and its application has
been further extended to flexible molecules [86, 87] and
protein surface loops [64]. After removing overall rotation
and translations, the atoms of the binding region are
superimposed using their Ca atoms coordinates. A matrix
that contains all pair-wise RMSD values among all the
structures in the trajectory is created. Next, the matrix is
divided into batches corresponding to similar structures
using the RMSD values, with a clustering algorithm [71]
and a user-defined cutoff. This clustering allows docking
trials to be performed on a reduced number of significant
conformations, while retaining the dominant characteristics
of the entire spectrum of binding modes.
In the case of the W191G cavity mutant of cytochrome c
peroxidase, re-docking into the entire ensemble of struc-
tures would require docking to 104 snapshots. However,
when these trajectory snapshots were clustered into groups
of similar configurations with a RMSD similarity criterion
of 0.1 nm for the cavity residues, the resulting two most
dominant clusters of trajectory structures represented 36
and 16%, 81 and 10%, 48 and 23% of the structures for the
apo, holo, and apo-open ensembles, respectively (Fig. 4b).
This RMSD clustering resulted in a 99% reduction of
computational cost for the RCS docking stage [69].
In addition to improving the computational efficiency of
the RCS, clustering analyses can also supply useful infor-
mation about the flexibility of the receptor, by analyzing
J Comput Aided Mol Des (2008) 22:693–705 699
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Fig. 4 Reducing redundancy in the receptor ensemble. (a) Left
panel: Multidimensional QR factorization of KREL1 determines the
distance relationship among all pairs of proteins (according to RMSD)
and then reorders them based on increasing linear dependence,
allowing the distillation of a reduced, representative set of structures
for docking. At any particular QH threshold (indicated by red dotted
line at QH 0.86), at each point of intersection of a branch, the most
linearly independent structure is chosen from the group to the right of
the dotted line (each red open circle drawn at the branch intersection
indicates the choice of one structure to represent all structures to the
right of the node). For clarity, the structure tree shown here is reduced
(not all KREL1 structures are shown). Right panel: the initial (top) set
of structures with the corresponding binding spectrum and the
reduced set (bottom) is shown. The similarity between the full and
reduced binding spectrums indicates that there is virtually no loss of
information. (b) Dominant configurations of the W191G cavity region
as extracted from RMSD conformational clustering. For each separate
MD ensemble the corresponding reference crystal configuration is
displayed (red thin lines) superimposed on the central member
structures of the first (yellow licorice) and second (green licorice)
most populated clusters.
700 J Comput Aided Mol Des (2008) 22:693–705
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the number of structures representing a certain QH or
RMSD threshold cutoff (in the QR factorization method) or
the cluster population versus the number of clusters pop-
ulated (in the RMSD clustering method). This type of
information gives quantitative insight about the local and
global flexibility of the receptor. The computational gain
due to these types of clustering schemes seems particularly
useful when screening large compound databases.
Choice of MD receptor ensemble and RCS predictive
power
One of the major challenges for hybrid docking techniques
is the possibility to screen large compound databases and
extract potential binders based on very limited a priori
knowledge of the binding process itself. In this context, the
W191G cytochrome c peroxidase system is used as a
platform to investigate how the choice of MD receptor
ensemble for RCS calculations affects the predictive power
of this methodology [69]. To reflect the different amounts
of knowledge that may be available on the binding process,
different typical scenarios in drug discovery were consid-
ered, including cases in which: (i) no information is
available on the location of the binding site, (ii) X-ray
structures of the protein–ligand complexes and knowledge
on potential binders is not available, and (iii) the X-ray
structures known for the protein–ligand complex do not
define unique ligand-binding poses. Corresponding to the
above scenarios: (i) the RCS technique using the holo-
receptor ensemble finds true positives using a docking grid
that encompasses the entire W191G cytochrome c peroxi-
dase structure; (ii) the number of true positives and true
negatives can be significantly increased versus the number
of false positives and false negatives by employing an
MD receptor ensemble containing a generalized type of
unphysical ligand that reflects the main structural proper-
ties of the compounds in the database, when compared to
equivalent docking calculations performed on the apo MD
receptor ensemble; and (iii) the multiple binding orienta-
tions characterizing the true positives do not necessarily
correspond to non-accurate docking results when compared
to the raw electron density data from X-ray crystallogra-
phy. The quality of the binding poses can be judged by a
combined evaluation of (i) the distribution of the docked-
ligand cluster populations versus the cluster number, (ii)
RMSD from the corresponding experimental complex after
superimposing the structures as described above, and (iii)
the comparison of the different poses for a same ligand.
These results open new possibilities for enhancing the
predictive power of RCS calculations in so-called ‘‘blind’’
test cases (when information is missing concerning the
binding process), and they also suggest that the best
possible choice of MD ensemble may depend on the
amount of knowledge available case by case. Additional
scenarios can be considered as well, for example including
homology-modeling type of approaches to generate the
initial receptor structural configuration.
Accurate description of solvent contributions
An effective representation of the solvent during the
docking trials is a major factor limiting the accuracy of
docking calculations. Until recently, RCS calculations have
been performed using only the receptor structure and
ligand, even when the MD trajectory structures were gen-
erated in combination with explicit water models.
Accounting for the specific role of conserved water mole-
cules is highly relevant as they may perturb the flexibility
of a bound ligand, significantly alter the electrostatic
environment experienced by a small molecule, and even
occlude potential areas of binding. The explicit inclusion of
these contributions will certainly improve the accuracy of
the ligand-binding description, similarly to what recently
reported for protein–protein docking [88]. Here, we present
two new applications of the RCS that tested docking of the
ligands into MD generated receptor structures with and
without cavity water molecules. What emerges from both
examples is the important (thermo)dynamic role of specific
waters for the binding process.
In the case of the RNA editing ligase, the KREL1 crystal
structure suggested three buried water molecules in the
deep end of the ATP binding pocket. Explicitly solvated
MD simulations of the holo complex (i.e., ATP bound)
allowed us to predict the dynamics of the crystal water
molecules. The simulations indicated that these water
molecules have different exchange rates, and that one of
the water molecules in particular, the one directly inter-
acting with both the protein and ATP, persists in its
original location for the duration of the 20 ns simulation
[63]. In terms of the receptor structure, this single coordi-
nated water molecule acts as a structural scaffold that
prevents the localized collapse of surrounding residues
while interacting with the bound ATP. By extracting the
water molecules from the structure before ligand docking,
an additional small cavity was open to the ligand. The RCS
dockings were performed both with and without the three
conserved water molecules. Interestingly, the best inhibi-
tors were identified when the water molecules were not
included in the RCS dockings. The predicted docking poses
and binding affinities differ significantly depending on
whether the three explicit conserved water molecules are
included in the dockings or not (data not shown). Impor-
tantly, at least two of the experimentally verified inhibitors
were predicted to substitute a functional group into the
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location where one of the crystal water molecules was
located (Fig. 5a) [68].
In the W191G cytochrome c peroxidase application,
several docking calculations were performed to investigate
the influence of the crystallographic water sites on Auto-
Dock binding affinities and ligand poses. The tests were
performed with rigid-protein docking calculations on dif-
ferent receptor models, alternatively including or excluding
water site 308, which was suggested to be a highly con-
served location for a bound water based on X-ray structures
for a large group of compounds [81]. The results from the
docking calculations are in agreement with what was pre-
viously suggested by similar tests based on AutoDock
version 3.0, which showed that the introduction of even a
single water molecule can significantly perturb the binding
propensity of most of the ligands [89].
While the effect on the predicted binding affinities and
poses is at variance with the specific ligand, a systematic
consequence of the introduction of one water molecule into
the W191G cavity is the significant reduction of the con-
figurational space available to the ligand during the
docking trials. MD simulations of the W191G cavity pre-
dict the location of the highly favorable water sites (within
X-ray crystallography resolution and refinement assump-
tions) compared with the available experimental data
(Fig. 5b). Additionally, MD simulations reveal a larger
number of favorable water sites, and allow the description
of the dynamic behavior of the solvent, including the
swapping of water molecules between highly favorable
regions [64]. Based on these observations we suggest that
the significant effects of including explicit water in the
static dockings may be an artificial consequence of the
introduction of bound (static) water molecules in the cav-
ity, whereas locally disordered (dynamically swapping
among the favorable sites) water molecules should be
considered instead. We note that an accurate sampling of
receptor, ligand, and solvent phase spaces is, in principle,
reached by more expensive free energy calculations [11,
26–36].
Future methodological improvements
The development of computational tools for computer-
aided drug design depends on the critical compromise
between accuracy and computational costs. Ideally, the
most reliable prediction of molecular affinity can be
obtained through rigorous free energy calculations of the
ligand-binding process [11, 26–36]. In practice, however,
the CPU time typically required to perform such free
energy calculations on a few candidates (bottom of the
funnel diagram in Fig. 1) is comparable to that involved in
rough geometrical recognition over a pool of molecules
more than five orders of magnitude larger (top of the funnel
diagram in Fig. 1). Although the theory and methods are
well established for calculating free energy in practice,
they are still prohibitively expensive to be employed in
high-throughput screening of drug-like databases. The
future development of hybrid techniques, and especially
the RCS, is therefore twofold.
First, it will certainly involve the refinement of the
underlying physical models describing ligand-binding
Fig. 5 Solvent contributions in protein–ligand binding. (a) The
KREL1 active site with one of the newly discovered inhibitors in a
predicted docked conformation. KREL1 is shown in orange cartoon,
with the novel inhibitor shown docked in the active site (licorice,
atom type colors). The three crystallographic water sites (not included
in the docking calculation) are shown in licorice with their van der
Waals surface in transparent. Note that the sulfonic acid group of the
inhibitor replaces the location of a crystal water molecule. (b) For the
W191G cavity (gray surface), the crystallographic water sites (solid
red spheres; diameter corresponding to X-ray resolution) are
compared to the highly favorable average density regions of water
molecules in the MD simulations (blue wireframe isosurfaces), for the
best binder 2a5mt (yellow licorice) and from the 1AEN crystal
structure (red licorice)
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(thermo)dynamics in increased detail, especially during the
docking stage. Although the results presented here include
the unbound (gas phase) ligand enthalpy term at the
docking stage [66], a complete description of the thermo-
dynamic cycle of binding is still far from being explicitly
treated in RCS. Previous studies investigated the benefits
of rescoring the docked complexes using a more accurate
(implicit solvent) description of the solvent contributions
[54]. More recently, the role of ligand entropy in the
refinement of protein–ligand docking predictions has been
evaluated [90, 91]. Additionally, accurate configurational
entropy calculations from MD simulations and a complete
quasi-harmonic analysis have demonstrated that the ther-
modynamic role of receptor flexibility is generally
underestimated [92]. Alternative strategies based on MM-
PBSA-type thermodynamic estimates, which involve the
implicit description of the solvation and desolvation ther-
modynamic effects involved in protein–ligand binding, are
being pursued. These terms are currently implemented in
the AutoDock 4.0 scoring functions on empirical basis
only. Using a more generally parameterized MD-type force
field to evaluate and rescore the docked complexes should
lead to more accurate estimates of the binding affinities, as
well as allow for increased transferability of the RCS to a
more diverse set of systems.
Second, concerning the final refinement procedure
(bottom of the funnel in Fig. 1): the application of accurate
(explicit solvent) free energy calculations for a larger
number of ligands and receptors of increasing size will
primarily be influenced by force field accuracy, the ability
to attain extensive sampling, and an improved description
of the enthalpy–entropy compensation thermodynamics.
Although the computational determination of free energy
changes has become a standard procedure for which a
variety of techniques have been developed, absolute
entropies and their differences are still rarely computed.
The rapid development of computer resources accompa-
nied by force field refinement and improved simulation
algorithms will naturally extend the range of problems that
free energy calculations can directly assess.
Conclusions
Accounting for receptor flexibility in computer-aided drug
design is still a major challenge. Recent examples illustrate
the importance of predicting and including induced-fit
effects upon receptor–ligand binding. MD simulations of
receptors in complex with known and potential inhibitors
provide relevant biochemical insights, which are otherwise
not accessible through standard experimental techniques.
Despite this, a general and highly transferable procedure
that reliably and efficiently accommodates receptor flexi-
bility is still lacking. The extensions and methodological
improvements to the RCS presented here take important
steps toward offering such a streamlined procedure. Our
examples indicate that alternative choices of receptor
ensembles can significantly alter the predictive power of
RCS calculations, and that it is possible to reduce the
receptor ensemble to a non-redundant set of configurations
by various techniques without losing relevant binding
information. Furthermore, both example systems indicate
that the role of explicit water molecules in molecular
association remains one of the key components of com-
puter-aided drug design methods to be further investigated.
A summary of the crucial points that we anticipate will
help drive the future development of the RCS was pre-
sented and what emerges is that a clear and pressing
challenge, closely coupled to receptor flexibility, is the
development of methods to better estimate ligand and
receptor entropy. Their subsequent application to molecu-
lar association thermodynamics will allow an increased
accuracy in the description of enthalpy-entropy compen-
sation effects during the ligand binding process.
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